Gardian

SENTRY

An AI-driven robotics and data platform that monitors environmental samples, banks bacteria and bacteriophage, and predicts antibiotic resistance. It utilizes deep learning to predict the resistance of bacterial species from their genomic sequences to clinically relevant antibiotics with 97% accuracy.

Advancing SENTRY with BARDA, adding new AMR Prediction capabilities

Monitor & Bank

Collect longitudinal samples from wastewater treatment facilities to isolate and bank bacteria and bacteriophage.

Sequence & Analyze

Perform deep, long-read shotgun metagenomic sequencing and assemble genomes to feed AI models.

Predict Antibiotic Resistance

Predict real-time antibiotic sensitivity profiles of circulating pathogens using deep learning and assess their trajectories toward AMR.

SHIELD

Intelligent automation rapidly creates optimized precision therapies. By employing AI-driven combinatorial biochemistry and phage engineering, Locus develops cocktails that selectively neutralize emerging bacterial threats. Clinical studies have demonstrated high success rates, including a 99.9999% average reduction in bacterial titer.

Intelligent automation provides unprecedented scale

Payload Discovery

Novel antibacterial payloads created with AI-driven combinatorial biochemistry that can increase killing efficacy and prevent emergence of resistance.

Phage Engineering

Ten years of phage synthetic biology generated massive data set of dispensable regions of phage genomes and optimal payload/promoter design to feed AI-driven engineering.

Cocktail Optimization

Quadrillions (>10¹⁵) of engineered phage combinations are computationally screened and top candidates experimentally tested – pinpointing cocktail that can eradicate the largest percentage of target strains.

SUPPLY

An ISPE award-winning domestic manufacturing facility that reduces reliance on foreign supply chains, the North Carolina facility supports GMP manufacturing, including high-throughput process development and sterile fill capabilities, with the capacity to produce millions of doses annually.

Advanced domestic biomanufacturing protects the supply chain for critical threat response

Process & Formulation Development

High-throughput upstream amplification optimization, platform purification methods, single-use-component processes, and FDA-supported parenteral, topical, and oral formulations that are stable for 3+ years drive repeatable “plug and play” manufacturing across assets.

GMP Manufacturing

Three-suite, 10,000 sq. ft. BSL-2 manufacturing facility supports US-based bulk drug substance and finished drug product manufacturing at up to 200 L scale per phage, producing millions of doses. Cytiva Microcell robotic isolator-filler for sterile DP fill.

Analytical Development & Testing

Platform methods and in-house GMP release testing minimize method development time and enable batches to be released within two weeks, limited only by the duration of the sterility test method.